Grand Pharmaceutical Group Limited (stock code: 00512) submitted its monthly return for the period ending 28 February 2026. According to the announcement, the total authorized share capital remained at HKD 1.00 billion, comprising 100.00 billion authorized ordinary shares at a par value of HKD 0.01 each.
The number of issued shares remained at 3.55 billion, with zero treasury shares outstanding. The public float continued to satisfy the required 25% threshold. The company indicated there were no outstanding share options, warrants, convertible securities, or other agreements to issue new shares during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments